Liver Transplantation

Study of peginterferon alfa-2b, ribavirin in liver transplant patients with HCV initiated

Published in Hepatitis Weekly, June 19th, 2006

Schering-Plough announced the initiation of a large multicenter clinical trial in the United States to evaluate the safety and efficacy of Peg-Intron (peginterferon alfa-2b) and Rebetol (ribavirin, USP) combination therapy in liver transplant recipients with recurrent hepatitis C virus (HCV) infection.

Known as the PROTECT study, the trial is targeted to enroll 125 HCV patients at approximately 28 liver transplant centers nationwide.

Hepatitis C is currently the indication for liver transplantation in the United States, (U.S. Centers for Disease Control and Prevention) and more than 17,000 Americans are awaiting liver transplants for all diagnoses...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2006-06-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry